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Summary Systemic chemotherapy using two-drug platinum-
based regimens for the treatment of advanced stage non-small
cell lung cancer (NSCLC) has largely reached a plateau of
effectiveness. Accordingly, efforts to improve survival and
quality of life outcomes have more recently focused on the
use of molecularly targeted agents, either alone or in combi-
nation with standard of care therapies such as taxanes. The
molecular chaperone heat shock protein 90 (Hsp90) represents
an attractive candidate for therapeutic intervention, as its inhi-
bition results in the simultaneous blockade of multiple onco-
genic signaling cascades. Ganetespib is a non-ansamycin
inhibitor of Hsp90 currently under clinical evaluation in a
number of human malignancies, including NSCLC. Here we
show that ganetespib potentiates the cytotoxic activity of the
taxanes paclitaxel and docetaxel in NSCLC models. The com-
bination of ganetespib with paclitaxel, docetaxel or another
microtubule-targeted agent vincristine resulted in synergistic
antiproliferative effects in the H1975 cell line in vitro. These
benefits translated to improved efficacy in H1975 xenografts in
vivo, with significantly enhanced tumor growth inhibition
observed in combination with paclitaxel and tumor regressions
seen with docetaxel. Notably, concurrent exposure to ganetes-
pib and docetaxel improved antitumor activity in 5 of 6
NSCLC xenograft models examined. Our data suggest that
the improved therapeutic indices are likely to be mechanisti-
cally multifactorial, including loss of pro-survival signaling
and direct cell cycle effects resulting from Hsp90 modulation
by ganetespib. Taken together, these findings provide preclin-
ical evidence for the use of this combination to treat patients
with advanced NSCLC.
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Introduction
Non-small cell lung cancer (NSCLC) accounts for 85% of all
cases of lung cancer, the leading cause of cancer-related
deaths worldwide [1]. This high mortality is associated, in
part, to the fact that a majority of patients present with ad-
vanced disease at the time of diagnosis with treatment options
limited to systemic therapy. Combination chemotherapy with
a platinum-based regimen is the foundation of current treat-
ment for patients with advanced NSCLC [2]. Two-drug com-
binations consisting of either cisplatin or carboplatin with an
additional ‘third-generation’ cytotoxic agent (paclitaxel, doce-
taxel, gemcitabine, vinorelabine, or pemetrexed) represent the
current standard of care for most patients [3]. Paclitaxel and
docetaxel comprise the taxane family of microtubule stabil-
izers widely used in the treatment of advanced NSCLC.
Docetaxel, the only agent that is approved for both first- and
second-line treatment of NSCLC [4], was also the first drug to
establish superior efficacy and tolerability over other third-
generation agents when used in combination with platinum
compounds [3]. Unfortunately, however, conventional che-
motherapy has largely reached a plateau of effectiveness in
improving survival rates for lung cancer patients [3, 4].
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In recent years the advent of new molecularly-targeted
agents and refinements to existing systemic therapies, such
as the addition of the vascular endothelial growth factor
(VEGF)-binding monoclonal antibody bevacizumab to plati-
num doublets, the epidermal growth factor receptor (EGFR)-
binding monoclonal antibody cetuximab or the use of EGFR
inhibitors erlotinib and gefitinib, as well as ELM4-ALK inhib-
itors such as crizotinib, have improved the therapeutic options
for treating this disease [5–7], resulting in modest improve-
ments in overall survival and quality of life for certain patient
populations. Despite this progress, treatment outcomes are
still considered disappointing [8]. Clearly, the development
and use of novel therapeutic strategies to effectively combat
NSCLC represents an urgent unmet medical need.
Heat shock protein 90 (Hsp90) is a molecular chaperone
required for the post-translational stability and function of
numerous key signal transduction proteins, termed ‘client’
proteins, many of which play critical roles in cell growth,
differentiation and survival [9, 10]. Importantly, it is now
recognized that the chaperoning activity of Hsp90 can become
subverted during tumorigenesis to help facilitate malignant
progression [9]. Since multiple signaling cascades are
regulated by this molecule, the effects of pharmacological
blockade of Hsp90 are transmitted to a variety of client pro-
teins and biochemical pathways. Because of this unique
characteristic, inhibition of Hsp90 can overcome signaling
redundancies and mechanisms of drug resistance commonly
observed in many cancers [11–13]. In addition, because tumor
cells contain elevated levels of the active form of the chaper-
one complex relative to normal cells, tumor cells have been
shown to be selectively sensitive to Hsp90 inhibition [14].
Thus, Hsp90 provides an attractive molecular target for the
development of novel anticancer agents [13, 15, 16].
Ganetespib (formerly STA-9090) is a potent and selective
small molecule Hsp90 inhibitor [17] currently being evalu-
ated in multiple clinical trials in solid tumor and hematolog-
ical malignancies. Recently, a Phase 2b/3 trial was initiated
in which it is being combined with docetaxel to treat patients
with advanced NSCLC. This indication is considered prom-
ising for the application of Hsp90 inhibitors [18] and,
importantly, has provided a compelling rationale for the
feasibility of combining Hsp90 inhibitors with other thera-
peutic agents. For example, mutated EGFR, a known Hsp90
client protein, is an important oncogenic driver in a subset of
NSCLC patients [19]. Accordingly, Hsp90 inhibitors have
demonstrated clinical efficacy when used in combination
with EGFR tyrosine kinase inhibitors (TKIs), even in indi-
viduals who had progressed on TKI therapy [20]. Of rele-
vance here, Hsp90 inhibitors have also been shown to
potentiate the cytotoxic effects of paclitaxel in multiple
tumor models, including NSCLC [21–24].
These considerations therefore prompted a more compre-
hensive evaluation of ganetespib activity in combination
with taxanes in preclinical models of NSCLC. In the present
study we show that combinatorial treatment results in syn-
ergistic antiproliferative and antitumor effects both in vitro
and in vivo. Our findings support the potential therapeutic
value of ganetespib, particularly in combination with doce-
taxel, for the treatment of patients with NSCLC.
Materials and methods
Cell lines, antibodies and reagents
All cell lines were obtained from the ATCC (Rockville,
MD) and were maintained according to standard techniques
at 37°C in 5% (v/v) CO2 using culture medium recommen-
ded by the supplier. All primary antibodies were purchased
from Cell Signaling Technology (CST, Beverly, MA). Gane-
tespib [3-(2,4-dihydroxy-5-isopropylphenyl)-4-(1-methyl-
1H-indol-5-yl)-1H-1,2,4-triazol-5(4H)-one] was synthe-
sized by Synta Pharmaceuticals Corp. Paclitaxel, docetaxel
and vincristine were purchased from LC Laboratories
(Woburn, MA).
Cell viability assays
Twenty fours hours after plating in 96 well plates, H1975
cells were dosed with graded concentrations of the indicated
compound or DMSO controls for 72 h. AlamarBlue (Invi-
trogen, Carlsbad, CA) was added (10% v/v) to the cells, and
the plates incubated for 3 h and subjected to fluorescence
detection in a SpectraMax Plus 384 microplate reader (Mo-
lecular Devices, Sunnyvale, CA). Data were normalized to
percent of control.
Western blotting
Following ganetespib treatment for 4 or 24 h, H1975 cells
were disrupted in lysis buffer (CST) on ice for 10 min.
Lysates were clarified by centrifugation and equal amounts
of protein resolved by SDS-PAGE before transfer to nitrocel-
lulose membranes (Invitrogen, Carlsbad CA). Membranes
were blocked with 5% skim milk in TBS with 0.5% Tween
and immunoblotted with the indicated antibodies. The
antibody-antigen complex was visualized and quantitated
using an Odyssey system (LI-COR, Lincoln, NE).
Cell cycle analysis
Docetaxel- and ganetespib-treated H1975 cells were incu-
bated with the respective compounds (0–30 nM) for 24 h
prior to harvest. Cells were fixed, washed and stained with
propidium iodide before being analyzed by flow cytometry.
The percentage of cells in each phase of the cell cycle
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(sub-G1, G1, S and G2/M) was determined from the FL2-A
histogram.
Median effect analysis
H1975 cells were seeded into the viability assay and com-
bination treatments of ganetespib with paclitaxel, docetaxel
or vincristine were performed at fixed, non-constant ratios
of the compounds. Drugs were added to cell cultures for
72 h and viability measured by alamarBlue assay. The
nature of the combinatorial interactions were evaluated
using the combination index (CI) method [25] and values
generated using Median Effect analysis (Calcusyn Software;
Biosoft, Cambridge, UK).
In vivo NSCLC tumor models
Female immunodeficient CB-17/Icr-Prkdcscid/Crl (SCID)
mice (Charles River Laboratories, Wilmington, MA) were
maintained in a pathogen-free environment, and all in vivo
procedures were approved by the Synta Pharmaceuticals
Corp. Institutional Animal Care and Use Committee in
accordance with the Guide for Care and Use of Laboratory
Animals. NSCLC cell lines were subcutaneously implanted
into mice. Mice bearing established tumors (~150 mm3)
were randomized into treatment groups (5–8 animals per
group) and i.v. dosed via the tail vein with ganetespib,
paclitaxel or docetaxel formulated in 10/18 DRD (10%
DMSO, 18% Cremophore RH 40, 3.8% dextrose) either as
single agents or concurrently on a 1X/week schedule. Tumor
volume measurements were made twice weekly and tumor
growth inhibition determined as described previously [26].
Statistical analysis
A mixed-model, repeated measures analysis of variance was
used to analyze the tumor growth inhibition data. The model
included the tumor measurement as dependent variable and
treatment (fixed effect), days after tumor implantation (fixed
effect), the interaction between treatment and days after
tumor implantation (fixed effect) and mice (random effect)
as independent variables. P-values are obtained from pair-
wise comparisons of each drug to the vehicle. SAS Version
9.1 was used for analysis.
Histological analysis and apoptosis assessment
Mice bearing established H1437 xenografts were adminis-
tered a single dose of ganetespib (50 mg/kg), docetaxel
(4 mg/kg), ganetespib plus docetaxel, or vehicle (10/18
DRD) for 24 h. Tumors were excised and formalin fixed.
Paraffin embedded sections were subject to immunohisto-
chemical staining for TUNEL expression using the ApopTag
Peroxidase ISOL Apoptosis Detection kit (Millipore,
Billerica, MA) according to manufacturers instructions.
Images were acquired using a Nikon E800 microscope and
Leica DC camera linked to Image-Pro plus software (Media
Cybernetics, Inc., Bethesda, MA). Image analysis was per-
formed using a total of 6 sections per slide at 20X magnifica-
tion. The percentage of apoptotic area was determined by the
Average apoptotic area/Average total area. Statistical signifi-
cance was determined using one-way ANOVA.
Results
Single agent activity in H1975 NSCLC cells
We initially examined the single-agent effects of ganetespib
or taxane treatment using the NSCLC cell line H1975. As
shown in Fig. 1a, ganetespib reduced cellular viability with
low nanomolar potency (IC50<10 nM), and exposure to
nanomolar concentrations of paclitaxel and docetaxel also
resulted in potent cytotoxic effects. H1975 cells were equally
sensitive to vincristine, a microtubule-targeted agent of the
vinca alkaloid class, which acts via a similar mechanism to the
taxanes by causing mitotic cell cycle arrest (Fig. 1a).
The H9175 cell line expresses EGFRL858/T790M, a consti-
tutively activated, erlotinib-resistant form of EGFR and an
Hsp90 client. Ganetespib exposure resulted in a time- and
dose-dependent degradation of this oncogenic driver, as
well as loss of its downstream effector p-STAT3 (Fig. 1b).
Further, inactivation of AKT and GSK3β, Hsp90 client
proteins important in regulating apoptosis, was observed
with a similar dose response to that of EGFR signaling
(Fig. 1b). Together, these data indicate that ganetespib
effectively inhibits Hsp90 client proteins in H1975 cells
sufficient to account for the cytotoxic response seen follow-
ing treatment.
Cell cycle analysis (Fig. 1c) confirmed the cellular activity
of docetaxel, which induced a dose-dependent mitotic arrest in
the G2/M phase of H1975 cells, with concomitant loss of G1
and S phases. Interestingly, ganetespib treatment resulted in an
accumulation of cells in the G2/M phase at the highest
concentration examined (30 nM) while also reducing the
number of cells in S phase. This finding is consistent with
our earlier report that ganetespib can additionally modulate
cell cycle regulatory proteins to exert its antitumor activity
[26].
Ganetespib synergizes with taxanes in vitro
Next we examined the potential for improved therapeutic
benefit in NSCLC by combining ganetespib with the stan-
dard of care agents paclitaxel and docetaxel. Because of the
similarities in mechanism and responses seen in Fig. 1a we
Invest New Drugs (2012) 30:2201–2209 2203
also included vincristine in the study. H1975 cells were
concurrently treated with ganetespib and each of the three
agents using fixed non-constant ratios. Combinatorial activ-
ity was assessed using the Median Effect method [25] to
determine whether the combinations exhibited antagonistic,
additive or synergistic activity (Supplementary Tables 1–3).
The results are summarized in the normalized isobolograms
shown in Fig. 2. Each point in the isobologram represents
the effect of an individual drug combination and the further
a point lays from the additive line the stronger the (syner-
gistic or antagonistic) impact of the combination. Combina-
tions of paclitaxel or docetaxel with ganetespib were highly
synergistic in these cells (Fig. 2a,b). The vincristine interac-
tion was more modest, although additive and synergistic
combinatorial benefit was observed at a number of doses
(Fig. 2c). These data clearly indicate that ganetespib can
potentiate the effects of taxanes in this NSCLC cell line.
Ganetespib in combination with paclitaxel or docetaxel
results in improved efficacy in the H1975 NSCLC xenograft
model in vivo
To examine whether the synergistic effects observed in vitro
translated to improved efficacy in vivo, mice bearing H1975
xenografts were treated with ganetespib and taxanes, both as
single agents and in combination. We have previously de-
termined that the highest non-severely toxic dose (HNSTD)
of ganetespib on a weekly dosing regimen is 150 mg/kg
[17]. As shown in Fig. 3a, weekly administration of sub-
optimal doses of ganetespib (50 mg/kg) and paclitaxel
(7.5 mg/kg) reduced tumor growth by 45% and 62%, re-
spectively. Consistent with the in vitro findings, concurrent
treatment with both drugs at the same dose level resulted in
a significant enhancement of antitumor activity, blocking
tumor growth by 93% (i.e., T/C value 7%). The com-
bination treatment was well tolerated, with no signifi-
cant loss of body weight seen after 3 weeks of dosing
(data not shown).
Next, mice were treated with ganetespib at 100 mg/kg,
which inhibited tumor growth by 85%, and a similar level of
inhibition (87%) was seen when docetaxel was administered
at 5 mg/kg (Fig. 3b). Even at these more efficacious doses,
combination treatment with ganetespib and docetaxel
resulted in an improved antitumor response, inducing 24%
tumor regression (Fig. 3b). Taken together, these results
indicate that the combination of ganetespib with taxanes
results in a superior therapeutic response compared to the
single-agent activity of any of the compounds alone.
Combination ganetespib plus docetaxel treatment inhibits
tumor growth in multiple NSCLC xenografts
To extend these findings, we evaluated the antitumor efficacy
of ganetespib plus docetaxel treatment in additional NSCLC
xenograft models. As shown in Fig. 4a, when delivered as a
single agent at 75 mg/kg, ganetespib potently inhibited
HCC827 tumor growth (T/C 26%). Docetaxel (4 mg/kg) also
inhibited tumor growth in this model (T/C 46%). Importantly,
the antitumor effects were enhanced and tumor growth was
Fig. 1 Single agent effects on cell viability, Hsp90 client protein
degradation and cell cycle distribution in H1975 NSCLC cells. a
H1975 cells were treated with ganetespib, paclitaxel, docetaxel or
vincristine over a broad dose range (0.1 to 330 nM) for 72 h and cell
viability assessed by alamarBlue staining. b Temporal and dose-
dependent effects on Hsp90 client proteins by ganetespib. H1975 cells
were treated with increasing concentrations of ganetespib for 4 and
24 h and cell lysates subject to immunoblotting using the indicated
antibodies. c H1975 cells were treated with the indicated doses of
docetaxel or ganetespib and cell cycle distribution determined by flow
cytometry 24 h post-treatment
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completely abrogated when the two agents were administered
concurrently (Fig. 4a).
In the H1437 NSCLC model, the combination of gane-
tespib (50 mg/kg) and docetaxel (4 mg/kg) was significantly
more efficacious than either agent alone (Fig. 4b). To make
correlations with the cellular responses produced by these
treatments, mice bearing H1437 xenografts were treated
with a single dose of vehicle, ganetespib, docetaxel or
ganetespib plus docetaxel, and their tumors were harvested
24 h later. These tissues were then analyzed by immunohis-
tochemistry to determine their apoptotic index following the
treatments (Fig. 4c). Consistent with the effects on tumor
growth, apoptotic induction in vivo correlated with the
tumor responses of each treatment (Fig. 4d).
In total, combination treatment of ganetespib with doce-
taxel was evaluated in six in vivo models of NSCLC and the
results are summarized in Fig. 5. In five of these models,
ganetespib markedly enhanced the antitumor activity of
docetaxel, with H2228-derived xenografts as the one excep-
tion. However these xenografts manifest the greatest sensi-
tivity to both ganetespib and docetaxel as single agents
alone (88% tumor growth inhibition, 30% tumor regression,
respectively). Thus it is reasonable to suggest that any
potential synergistic effects in this line are likely to be
masked at the dosing level examined. Overall, our data
show that the addition of ganetespib to docetaxel regimens
strongly enhances the antitumor activity of the taxane in
vivo.
Discussion
Providing improved treatment options for NSCLC remains a
daunting challenge for clinicians and oncologists world-
wide. Systemic combination chemotherapy is considered
the standard of care for patients with advanced NSCLC
despite intense efforts at modifying treatments toward im-
proving survival outcomes [3]. The use of standard chemo-
therapy is restricted to a defined number of cycles, as
continuation results in added toxicity without meaningful
improvements in progression-free or overall survival [27].
Fig. 2 Median effect analysis of the combinatorial activity of ganetes-
pib with paclitaxel, docetaxel and vincristine in H1975 cells in vitro.
Drugs were added to H1975 cells at fixed, non-constant concentration
ratios for 72 h and viability assessed by Alamar blue assay. Each point
represents a CI value for a specific combination of drug concentrations.
Data points below the line in the isobologram represent synergy,
whereas data points above indicate antagonism between the drug pairs.
a Isobologram analysis of ganetespib in combination with paclitaxel. b
Isobologram analysis of ganetespib in combination with docetaxel. c
Isobologram analysis of ganetespib in combination with vincristine
Fig. 3 In vivo activity of ganetespib in combination with paclitaxel or
docetaxel in H1975 xenografts. a Human NSCLC H1975 tumor-
bearing SCID mice were i.v. dosed with ganetespib (50 mg/kg) and
paclitaxel (7.5 mg/kg) alone or in combination on a 1X/week schedule
for 3 weeks. Data represent the mean and S.E.M. The combination of
ganetespib and paclitaxel displayed significantly greater efficacy than
either agent alone (*, p<0.05). b Human NSCLC H1975 tumor-
bearing SCID mice were i.v. dosed with ganetespib (100 mg/kg) and
docetaxel (5 mg/kg) alone or in combination on a 1X/week schedule
for 3 weeks. Data represent mean and S.E.M. The combination of
ganetespib and docetaxel resulted in tumor regression (24%)
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The addition of a third cytotoxic agent to the two-drug
combination has been evaluated, however no differences in
efficacy were seen and the toxicity profile worsens [28].
More recently, the use of maintenance therapy has evolved
as a promising treatment option for NSCLC, based on
emerging clinical data using novel molecularly targeted
agents or chemotherapeutic drugs that exhibit a more favor-
able therapeutic index [6, 27].
One strategy to improve objective response rates in
patients is through the use of molecularly targeted agents
in combination with front line chemotherapeutics, such as
bevacizumab and cetuximab. Indeed, combining compli-
mentary agents that possess different presumed mechanisms
of action and non-overlapping toxicities has proven impor-
tant for the control of many human malignancies [29]. This
biologically rational approach in NSCLC has revealed that
benefit from targeted therapy combinations [5] is typically
observed within subsets of patients and correlates with
specific tumor histology and/or molecular phenotypes [8].
The coordinate impact of Hsp90 blockade on multiple on-
cogenic pathways and processes, as well as substantial
evidence of the clinical promise of using Hsp90 inhib-
itors in combination with other therapeutic agents [30],
provide a compelling rationale for investigating novel
combinatorial strategies. Ganetespib is a next generation
Hsp90 inhibitor, structurally unrelated to the prototypic
ansamycin class, which exhibits superior pharmacologic
and biological properties in terms of potency and safety
[17]. Accordingly, an important finding of this study is
that ganetespib greatly enhances the efficacy of chemo-
therapeutics commonly used in the treatment of advanced
NSCLC.
Fig. 4 Combination of ganetespib and docetaxel induces enhanced
antitumor efficacy and apoptosis in NSCLC xenografts. a SCID mice
bearing HCC827 NSCLC xenografts were i.v. dosed with ganetespib
(75 mg/kg) and docetaxel (4 mg/kg) alone or in combination on a 1X/
week schedule for 4 weeks. Data represent the mean and S.E.M. b
SCID mice bearing H1437 xenografts were i.v. dosed with ganetespib
(50 mg/kg) and docetaxel (4 mg/kg) alone or in combination on a 1X/
week schedule for 4 weeks. Data represent the mean and S.E.M. The
combination of ganetespib and docetaxel displayed significantly
greater efficacy than either agent alone (*, p<0.05). c H1437 tumor-
bearing SCID mice were treated with a single dose of vehicle, ganetes-
pib (50 mg/kg), docetaxel (4 mg/kg) or ganetespib plus docetaxel and
tumors harvested 24 h later. Immunohistochemical staining for
TUNEL positivity (apoptosis) of tumor cross sections from vehicle
control, ganetespib, docetaxel, or ganetespib + docetaxel treated ani-
mals. Original magnification, 40X. d Quantitation of TUNEL-positive
areas of tumors as described in (C). Data represent the mean and S.D.
(*, p<0.05; one-way ANOVA)
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Here we showed that ganetespib synergistically potenti-
ated the cytotoxic and antitumor activity of paclitaxel or
docetaxel in a panel of NSCLC cell lines both in vitro and
in vivo. As a single agent, ganetespib treatment resulted in
loss of EGFR client protein expression and blockade of
AKT signaling in the H1975 cell line, and significantly
suppressed H1975 tumor growth in vivo when used in
combination with paclitaxel or docetaxel. These findings
are in agreement with a previous report showing that deg-
radation of mutant EGFR and inhibition of AKT activity by
the ansamycin Hsp90 inhibitor 17-allyamino-17-demethox-
ygeldanamycin (17-AAG) could sensitize NSCLC tumors to
paclitaxel [24]. In addition, the Hsp90 inhibitor CUDC-305
was recently shown to potentiate paclitaxel activity in
H1975 xenografts [31] where it was proposed that this
occurred, at least in part, via suppression of AKT. Other
studies in breast and ovarian cancer cell lines have also
suggested that suppression of AKT activity by 17-AAG
resulted in an enhanced sensitivity to the proapoptotic
effects of paclitaxel [23, 32]. In this regard, we have addi-
tionally found that ganetespib treatment promotes synergis-
tic improvements in docetaxel activity in breast, colon and
prostate cell lines (D. Proia, unpublished observations).
Taken together, these data imply that the modulation of
Hsp90 function and consequent loss of pro-survival path-
ways may render cancer cells more susceptible to taxane
treatment, and that this mechanism is conserved across
tumor types.
However, the mechanism(s) by which ganetespib
achieves improved therapeutic indices in combination with
taxanes is likely to be multifactorial. Other, not mutually
exclusive, molecular interactions likely exist - including
complementary effects of ganetespib on the cell cycle ma-
chinery that enhance taxane activity. Paclitaxel and doce-
taxel each cause microtubule stabilization, mitotic arrest of
cycling tumor cells, and subsequent apoptosis. Ganetespib
treatment itself exerts profound effects on cell cycle regula-
tory proteins, in addition to oncogenic signaling pathways,
that contribute to its potent antitumor activity [26]. Further,
it is known that mitotic catastrophe can be exacerbated by
Hsp90 inhibition in cell lines with defects in the function of
the cell checkpoint regulators BRCA1 [33] and RB [22], an
effect presumably linked to interference with Hsp90’s role
in centrosome organization [34, 35]. The Hsp90 client pro-
tein CRAF has also now been shown to localize to the
mitotic spindle of proliferating tumor cells to promote pro-
gression in a MEK-independent manner [36]. Inhibition of
this process results in prometaphase arrest thus providing
another avenue for targeted mitotic interference by Hsp90
inhibitors. It is reasonable to suggest, therefore, that modu-
lation of the cell division machinery may represent an im-
portant component of the cytotoxic sensitizing property of
ganetespib. This premise is supported by our findings that
additive and synergistic benefit was also seen for ganetespib
in combination with vincristine, another microtubule-
targeted agent that induces mitotic arrest prior to cell death.
Notably, we observed that concurrent exposure to gane-
tespib and docetaxel was significantly more efficacious than
either agent alone in 5 of 6 xenograft models in mice bearing
established NSCLC tumors. In the one exception, H2228
cells, it appeared that the concentrations tested masked any
potential benefit as each drug alone caused pronounced
antiproliferative effects. These data have important clinical
considerations. Docetaxel is the only agent that is approved
for both first- and second-line therapy in advanced NSCLC
[4]. Meta-analyses of the current treatment regimens for
these patients have shown that docetaxel is associated with
better disease control than paclitaxel combinations [3]. In
addition, tumor histology does not exert any influence over
the activity or efficacy of docetaxel, as opposed other third-
generation cytotoxics [3]. Thus, docetaxel represents an
optimal front line candidate for combination with a
targeted agent such as ganetespib. In light of these
observations, we have recently initiated a Phase 2b/3
trial evaluating this combination in patients with refractory
NSCLC.
In summary, the capacity of ganetespib to potentiate the
cytotoxic effects of taxanes, in particular docetaxel, pro-
vides a molecular rationale for combining these agents as a
clinical strategy for NSCLC. Overall, the data presented
here provide strong preclinical support for the exploration
of this combination as a novel therapeutic approach in
patients suffering from this disease.
Fig. 5 Comparative antitumor activity of combination ganetespib plus
docetaxel treatment in NSCLC xenograft models. Summary of anti-
tumor efficacy of ganetespib and docetaxel either alone or in combi-
nation in 6 NSCLC xenograft models.%T/C values are reported.
Ganetespib was dosed at 50 mg/kg except for HCC827 (75 mg/kg)
and H1975 (100 mg/kg). Docetaxel was dosed at 4 mg/kg except for
H1975 (5 mg/kg)
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